Researchers say GLP-1 drugs prescribed for weight loss like Ozempic and Mounjaro are more effective at reducing heart health ...

Marketing and manufacturing practices for compounded GLP-1RA drugs have come under FDA scrutiny, prompting policy changes.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have garnered significant attention recently, both in the media and in ...

A recent study reveals significant barriers to GLP-1 RA access for diabetes and obesity patients, highlighting racial disparities and high costs. An alarming 40% of orders for glucagon-like peptide-1 ...

Just a year after emerging from stealth with a nearly half a billion dollars, Kailera Therapeutics has reached another ...

GLP-1RA use was associated with a lower risk for delirium within 5 years of use but a higher risk for delirium within 5 to 10 years of use among patients with type 2 diabetes. Delirium risk initially ...

Compared with nonuse, GLP-1RA and thiazolidinedione combination therapy reduced risks for all-cause and cardiovascular mortality in type 2 diabetes. The combination of a glucagon-like peptide 1 ...

USA: A new study published in Arthritis & Rheumatology found that patients with lupus and type 2 diabetes, including those ...

In this cohort study, 40% of orders for glucagon-like peptide-1 receptor agonists (GLP-1RAs) were not filled. Non-Hispanic Black patients and Hispanic patients were less likely to fill orders than non ...

The biotech currently has four programmes in the clinic. Its lead candidate is MET-097i, a weekly and monthly injectable GLP-1RA, both in Phase II development (NCT06897202 and NCT06973720). Phase IIa ...

PATIENTS with systemic lupus erythematosus (SLE) and Type 2 diabetes (T2D) had significantly lower cardiovascular, kidney, ...

While GLP-1 receptor agonists like semaglutide help with weight loss, new research shows users often fall short on vital nutrients, spotlighting the urgent need for tailored dietary guidance. Study: ...